Loading patent…
AssigneesEcole Normale Superieure De Lyon, Centre National de la Recherche Scientifique (CNRS), Universite Claude Bernard Lyon 1, Institut National De La Sante Et De La Recherche Medicale (Inserm)
InventorsCaroline Costa Fejoz, Els Verhoeyen, François-Loïc Cosset, Ruben Bender, Christian Buchholz, Qi Zhou
Estimating the term…
The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.
A pseudotyped lentiviral vector comprising:
A pseudotyped lentiviral vector comprising:
A pseudotyped lentiviral vector comprising:
Dependencies are inferred from the claim text.